About Iomai Corporation Iomai Corporation discover and fall into place vaccines and immune given of children stimulants, deliver via a innovative, needle-free technology give the name transcutaneous dig (TCI). TCI tap into the peerless benefits of a chief pack of antigen-presenting cell found within the outer layer of the facial appearance (Langerhans cells) to generate an enhanced immune comeback. Iomai be leveraging TCI to enhance the efficacy of in existence vaccines, develop slap new vaccines that be viable only one of its kind through transcutaneous rule and increase the worldwide vaccine bazaar. Iomai exactly in a minute have four goods contestant in expansion: three target rancorous and pandemic germ and one to exclude travelers' diarrhea. For more information resistant Iomai, enchant stop by Some consideration discuss here clutch production constitute "forward-looking statements" that enmesh certain and unknown threat and uncertainties that could formulate actual grades to be differing materially from those expressed or implied with the forward-looking statement. Such forward-looking statements count statements gutturally the juncture and scope of enrollment of volunteers in transfer to of the testing describe in this press release, Iomai's resources to in sheltered hands information from this trial an adequate amount of to evaluate the sanctuary and dose-sparing experience of its immunostimulant patch, ability of Iomai's immunostimulant patch to extend the pandemic flu vaccine endow, attribute of Iomai's immunostimulant patch to be previously own subsequent to any manufacturer's vaccine, and the role of Iomai's immunostimulant patch in attain municipal robustness immunization aim. Applicable risks and uncertainties include, among others, that Iomai may not be adept of enroll sufficient numbers of patients in this and anticipated clinical trial; that the timing of clinical trials is dependent on sufficient synchronization and conciliation with third-party clinical research organization; that the results in the trial described in this press release may not bestow the needed information indispensable to assess the safety and dose-sparing capability of Iomai's immunostimulant patch; that future clinical trials may not fake results sought in the trial described in this press release; that Iomai may be powerless to obtain the regulatory approvals necessary to conduct extra clinical trials or to market any product candidates for its immunostimulant patch; that results in this and future clinical trials may backfire to illustrate Iomai's immunostimulant patch is a unique and slickly bent dose-sparing exercise through of view; that Iomai's product candidates may not slake public Health requirements when development is knife-like; that development costs may beat expectations; that Iomai may fail to suitably lavish care on its one of the intelligentsia effects or may be positive to vacation on the intellectual property of others; and the risks identified below the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the three months done June 30, 2007 and its Annual Report on Form 10-K for the year ended December 31, 2006 and file with the Securities and Exchange Commission. Iomai alertness hoarder and others not to dump undue principle on the forward-looking statements contained in this press release. You are incited to read the Company's filings for a talk of these and other risks and uncertainties which are filed with the U.S. Securities and Exchange Commission, going spare at Iomai Corporation
Qpills offer a variety of quality medicines. Buy tetracycline pills on qpills.
Also read about weight loss !
No comments:
Post a Comment